AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales

AnaptysBio

04/11/2025 22:07

Overview

AnaptysBio Q3 collaboration revenue rises significantly due to GSK milestone achievements

Company plans to separate biopharma operations from royalty assets by YE 2026

AnaptysBio reports Q3 net income, contrasting with a loss in the prior year

Outlook

AnaptysBio plans to separate biopharma operations from royalty assets by YE 2026

Company expects $75 mln milestone from GSK's Jemperli sales in Q4 2025

AnaptysBio expects annualized Jemperli royalties of >$390 mln before 2031

Result Drivers

GSK MILESTONE - Collaboration revenue boosted by $50 mln milestone from GSK's Jemperli sales exceeding $750 mln

BIOPHARMA SEPARATION - Intent to separate biopharma operations from royalty assets by YE 2026 to unlock value

ROSNILIMAB DATA - Positive Phase 2b data for rosnilimab in rheumatoid arthritis highlighted at ACR Convergence 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$76.32 mln
Q3 Net Income
$15.11 mln
Q3 Income From Operations
$34.70 mln
Q3 Operating Expenses
$41.61 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for AnaptysBio Inc is $62.00, about 41.9% above its November 3 closing price of $36.04

Press Release: ID:nGNX5Gv9LF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)